Russell Investments Group Ltd. Buys 309,436 Shares of LifeMD, Inc. $LFMD

Key Points

• Russell Investments increased its LifeMD position by 5,801.2% in the second quarter, acquiring 309,436 additional shares for a total stake of 314,770 shares, worth approximately $1.3 million. Institutional investors and hedge funds collectively own 35.52% of the company.
• LifeMD’s latest quarterly results fell short of expectations, with a loss of $0.16 per share versus the $0.15 consensus estimate and revenue of $47.28 million versus $49.16 million expected. The stock opened at $3.45, well below its 12-month high of $7.32.
• Analyst sentiment remains a “Moderate Buy”, with eight Buy ratings and two Sell ratings and an average price target of $7.57. However, analysts have lowered several earnings forecasts, underscoring uncertainty about the timing of profitability.

Russell Investments Group Ltd. lifted its position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 5,801.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 314,770 shares of the company's stock after acquiring an additional 309,436 shares during the period. Russell Investments Group Ltd. owned approximately 0.65% of LifeMD worth $1,300,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock valued at $270,000 after purchasing an additional 2,235 shares during the period. Tower Research Capital LLC TRC raised its holdings in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after purchasing an additional 2,452 shares during the period. SG Americas Securities LLC raised its holdings in LifeMD by 13.8% in the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company's stock worth $86,000 after purchasing an additional 3,061 shares during the period. Invesco Ltd. boosted its position in shares of LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company's stock worth $83,000 after purchasing an additional 3,870 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company's stock worth $730,000 after purchasing an additional 4,281 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Down 0.3%

Shares of LFMD stock opened at $3.45 on Friday. LifeMD, Inc. has a 12-month low of $2.56 and a 12-month high of $7.32. The firm has a fifty day moving average of $4.26 and a 200-day moving average of $3.96. The company has a market capitalization of $166.29 million, a price-to-earnings ratio of -68.99 and a beta of 2.02.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The company had revenue of $47.28 million during the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. On average, equities analysts expect that LifeMD, Inc. will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. UBS Group restated a "buy" rating on shares of LifeMD in a research report on Wednesday, May 27th. HC Wainwright reduced their target price on LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Weiss Ratings reissued a "sell (d)" rating on shares of LifeMD in a research note on Tuesday, August 4th. BTIG Research lowered their price target on LifeMD from $10.00 to $9.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Finally, KeyCorp set a $5.00 price target on LifeMD and gave the stock an "overweight" rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $7.57.

More LifeMD News

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $9.00 price target, well above recent trading levels, suggesting substantial upside if LifeMD executes on its longer-term growth plans. The firm raised its Q4 2026 EPS forecast to $0.06 from $0.02, FY2026 EPS to $(0.46) from $(0.47), Q1 2027 EPS to $(0.07) from $(0.09), and Q4 2027 EPS to $0.17 from $0.15. LifeMD analyst estimates
• Neutral Sentiment: The revisions imply a choppy path to profitability. HC Wainwright projects a $(0.46) loss for FY2026 and a $(0.12) loss for FY2027, although it expects LifeMD to produce positive earnings in Q4 2026 and Q4 2027.
• Negative Sentiment: The analyst cut its Q3 2026 EPS estimate to $(0.15) from $(0.05), Q2 2027 to $(0.13) from $(0.12), Q3 2027 to $(0.09) from $0.06, and FY2027 to $(0.12) from $(0.01). The FY2027 reduction is particularly significant because it indicates profitability may arrive more slowly than previously expected.
• Negative Sentiment: LifeMD’s latest quarterly results also showed modest pressure, with EPS of $(0.16) missing the $(0.15) consensus estimate and revenue of $47.28 million below the $49.16 million forecast. The company remains unprofitable, increasing investor sensitivity to downward estimate changes.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source